Cargando…
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies
The MET gene, known as MET proto-oncogene receptor tyrosine kinase, was first identified to induce tumor cell migration, invasion, and proliferation/survival through canonical RAS-CDC42-PAK-Rho kinase, RAS-MAPK, PI3K-AKT-mTOR, and β-catenin signaling pathways, and its driver mutations, such as MET g...
Autores principales: | Rivas, Solange, Marín, Arnaldo, Samtani, Suraj, González-Feliú, Evelin, Armisén, Ricardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697723/ https://www.ncbi.nlm.nih.gov/pubmed/36430388 http://dx.doi.org/10.3390/ijms232213898 |
Ejemplares similares
-
Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?
por: Renner, Alex, et al.
Publicado: (2019) -
MET in glioma: signaling pathways and targeted therapies
por: Cheng, Fangling, et al.
Publicado: (2019) -
Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
por: Huang, Xing, et al.
Publicado: (2020) -
Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches
por: Kumaki, Yuichi, et al.
Publicado: (2023) -
Opportunities and challenges of targeting c-Met in the treatment of digestive tumors
por: Zhang, Zhengchao, et al.
Publicado: (2022)